Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Total Valuation
ArriVent BioPharma, Inc. has a market cap or net worth of $1.06B. The enterprise value is $1.01B.
Market Cap$1.06B
Enterprise Value$1.01B
Share Statistics
ArriVent BioPharma, Inc. has 44,201,622 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,201,622
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ArriVent BioPharma, Inc.’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -57.78%.
Return on Equity (ROE)-0.54
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-57.78%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee0.00
Profits Per Employee-3.20M
Employee Count52
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ArriVent BioPharma, Inc. is ―. ArriVent BioPharma, Inc.’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio2.52
Price to Fair Value2.52
Price to FCF-4.82
Price to Operating Cash Flow-5.72
PEG Ratio-0.07
Income Statement
In the last 12 months, ArriVent BioPharma, Inc. had revenue of 0.00 and earned -166.31M in profits. Earnings per share was -4.32.
Revenue0.00
Gross Profit0.00
Operating Income-177.53M
Pretax Income-166.31M
Net Income-166.31M
EBITDA-177.53M
Earnings Per Share (EPS)-4.32
Cash Flow
In the last 12 months, operating cash flow was -160.59M and capital expenditures 0.00, giving a free cash flow of -160.59M billion.
Operating Cash Flow-160.59M
Free Cash Flow-160.59M
Free Cash Flow per Share-3.63
Dividends & Yields
ArriVent BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.93
52-Week Price Change16.25%
50-Day Moving Average22.55
200-Day Moving Average21.15
Relative Strength Index (RSI)51.77
Average Volume (3m)569.45K
Important Dates
ArriVent BioPharma, Inc. upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
ArriVent BioPharma, Inc. as a current ratio of 12.83, with Debt / Equity ratio of <0.01%
Current Ratio12.83
Quick Ratio12.83
Debt to Market Cap<0.01
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ArriVent BioPharma, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ArriVent BioPharma, Inc. EV to EBITDA ratio is -4.10, with an EV/FCF ratio of -4.54.
EV to Sales0.00
EV to EBITDA-4.10
EV to Free Cash Flow-4.54
EV to Operating Cash Flow-4.54
Balance Sheet
ArriVent BioPharma, Inc. has $312.82M in cash and marketable securities with $14.00K in debt, giving a net cash position of $312.81M billion.
Cash & Marketable Securities$312.82M
Total Debt$14.00K
Net Cash$312.81M
Net Cash Per Share$7.08
Tangible Book Value Per Share$7.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ArriVent BioPharma, Inc. is $42.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.33
Price Target Upside77.11% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast-75.31%